Evidence map›Paper›PMID 32124097›Full record

ReviewCurrent neurology and neuroscience reports2020

Update on Pediatric Optic Neuritis.

Ryan A Gise, Gena Heidary

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current neurology and neuroscience reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Ryan A GiseDepartment of Ophthalmology, Boston Children's Hospital, 300 Longwood Ave, Boston, MA, 02115, USA.
Gena HeidaryDepartment of Ophthalmology, Boston Children's Hospital, 300 Longwood Ave, Boston, MA, 02115, USA. Gena.Heidary@childrens.harvard.edu.
Boston Children's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThe purpose of this review is to provide an update on advances in the understanding of pediatric demyelinating optic neuritis. RECENT

findingsIn the past decade, the disease phenotypes for demyelinating syndromes in children have been more clearly defined. Pediatric optic neuritis may present as a clinically isolated syndrome or in the setting of underlying neurologic disease. In addition to optic neuritis associated with multiple sclerosis or neuromyelitis optica, recent work has identified antibodies to the myelin oligodendrocyte glycoprotein (MOG IgG) as a unique demyelinating cause with distinct features regarding treatment and prognosis. The disease phenotypes for demyelinating pediatric optic neuritis have expanded. Treatment strategies vary and are not universally effective for each cause of demyelinating disease. Accurately distinguishing among these unique clinical syndromes is therefore critical for initiation of appropriate treatment to prevent disability, to maximize visual outcomes, and to provide insight into long-term prognosis.

Indexed as

Multiple SclerosisNeuromyelitis OpticaOptic NeuritisAquaporin 4AutoantibodiesChildHumansMyelin-Oligodendrocyte GlycoproteinAquaporin 4AutoantibodiesMyelin-Oligodendrocyte GlycoproteinChronic relapsing inflammatory optic neuropathyDemyelinating diseaseMyelin oligodendrocyte glycoproteinNeuromyelitis opticaPediatric optic neuritis

Identifiers

PMID32124097
OpenAlexW3010359493

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.